CDKN2A and melanoma: Analyzing 26 studies comprising 979 melanomas and 974 nevi, the authors reported that the diagnostic performance of p16 loss is limited, with a pooled sensitivity of 0.55 (95% CI: 0.38–0.70) and specificity of 0.85 (95% CI: 0.70–0.94).